Drug intelligence / Profile preview

NDC-026

Development stage: Preclinical
Lead developer: DR.Noah Biotech

Overview

NDC-026 is an investigational drug developed by DR.NOAH BIOTECH for the treatment of Duchenne muscular dystrophy (DMD). It has received both rare pediatric disease designation and orphan drug designation from the U.S. FDA as of April 2024. The drug is being advanced using DR.NOAH's proprietary AI-driven platform, ARK, which specializes in identifying novel therapeutic candidates for rare diseases. As of September 2024, NDC-026 is in preclinical development with plans to submit an IND application in 2025. Specific details regarding its mechanism of action, molecular modality, or formulation have not been publicly disclosed[1][2].

Beyond the preview

Go deeper on NDC-026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NDC-026.

Explore the full profile